A study on patients with advanced cancers reported that first, antibiotics reduced ICIs’ clinical benefits and second, FMT from cancer patients who responded to ICIs into germ-free or antibiotic-treated mice ameliorated the antitumor effects of PD-1 blockade [78]. This evidence concerns the gene PDCD1 and cancer.